CR4 Antibody

What is CR4 and what are its alternative designations in scientific literature?

CR4 is an alias for the gene "Teratocarcinoma-derived growth factor 1 pseudogene 4" in humans. In the scientific literature, CR4 is also known by several other designations including CR-4, CRIPTO-4, and TDGF4. Additionally, CR4 is identified as CD11c/CD18, which is a β2-integrin primarily expressed on myeloid cells and activated memory B lymphocytes. The gene shares homology with other species, including mouse and Arabidopsis . Understanding these alternative designations is crucial when conducting literature searches or designing experiments targeting CR4, as papers may use different nomenclature depending on the research context or publication date.

How do I choose the appropriate anti-CR4 antibody for my specific experimental application?

Selecting the appropriate anti-CR4 antibody depends on several experimental factors:

• Application compatibility: Determine if the antibody has been validated for your specific application (Western blot, flow cytometry, immunohistochemistry, etc.)

• Epitope recognition: Consider whether you need antibodies that recognize specific domains of CR4

• Conjugation requirements: Assess whether you need unconjugated antibodies or those conjugated to fluorophores, enzymes, or other tags based on your detection method

• Species cross-reactivity: Verify whether cross-species reactivity is needed, as CR4 shares homology with other species including mouse

• Clonality: Determine whether monoclonal specificity or polyclonal broad epitope recognition better suits your research questions

Testing multiple antibody clones in pilot experiments is recommended to identify the optimal antibody for your specific experimental system.

What are the optimal protocols for detecting CR4 expression on activated memory B cells?

For detecting CR4 expression on activated memory B cells, flow cytometry represents the most robust methodology. The following protocol has been validated in research settings:

• Isolation: Isolate B cells from peripheral blood or tonsil tissue using negative selection to avoid activation

• Activation: Activate B cells through BCR stimulation (anti-IgM/IgG antibodies), typically for 24-72 hours

• Staining procedure:

  • Use anti-CD11c (CR4) antibodies in conjunction with memory B cell markers (CD27, IgG)

  • Include CD19 or CD20 to identify B cells

  • Add class switch markers to correlate CR4 expression with class switching

• Gating strategy: First gate on viable B cells (CD19+/CD20+), then analyze CR4 expression on memory (CD27+) versus naive (CD27-) populations

• Controls: Include fluorescence minus one (FMO) controls for CD11c to accurately determine positive populations

Remember that CR4 expression increases with B cell activation, so time-course experiments may be necessary to capture optimal expression windows.

How can I assess the functional activity of CR4 on B lymphocytes?

To assess the functional activity of CR4 on B lymphocytes, researchers can implement several complementary approaches:

• Adhesion assays:

  • Coat plates with CR4 ligands (e.g., fibrinogen, ICAM-1)

  • Compare adhesion of CR4+ versus CR4- B cells

  • Use anti-CR4 blocking antibodies to confirm specificity

  • Quantify adherent cells through microscopy or plate reader-based methods

• Migration assays:

  • Implement transwell migration assays with CR4 ligands as attractants

  • Compare migration of CR4+ and CR4- B cell populations

  • Include anti-CR4 blocking antibodies as controls

  • Analyze results as chemotactic index or percent migration

• Proliferation assessment:

  • Label B cells with proliferation dyes (CFSE, CellTrace)

  • Activate cells with and without CR4 engagement

  • Measure proliferation by dye dilution via flow cytometry

  • Calculate proliferation index and division index

These functional assays should be performed in parallel to comprehensively understand CR4's role in B cell biology.

What controls are essential when working with CR4 antibodies?

When working with CR4 antibodies, the following controls are essential for experimental rigor:

• Isotype controls: Include appropriate isotype-matched control antibodies to assess non-specific binding

• Blocking experiments: Perform pre-incubation with unlabeled CR4 antibodies to confirm specificity

• Knockdown validation: Where possible, include CR4 knockdown or knockout cells to confirm antibody specificity

• Positive controls: Include cell types known to express high levels of CR4 (e.g., dendritic cells for CD11c/CD18)

• Negative controls: Include cell populations that do not express CR4

• Functional blocking controls: When performing functional studies, include alternative blocking methods that target the same pathway through different mechanisms

• Antibody titration: Perform titration experiments to determine optimal antibody concentration for signal-to-noise ratio optimization

Implementing these controls ensures that observations are specifically attributed to CR4 and not to experimental artifacts.

How does the structural design of antibodies targeting CR4 affect their functionality?

The structural design of antibodies targeting CR4 significantly impacts their functionality, particularly regarding their ability to access binding sites and modulate CR4 activity. Key considerations include:

• CDR length and composition: Complementarity determining regions (CDRs) with tailored length and amino acid composition can enhance specificity and affinity for CR4. The rational design of elongated CDRs can create antibodies with unique binding properties, similar to approaches used for developing antibodies against other receptors like CXCR4 .

• Epitope targeting: Antibodies targeting different epitopes of CR4 may induce distinct functional outcomes:

  • Antibodies targeting the ligand-binding domain may block natural interactions

  • Antibodies targeting regulatory domains may modulate signaling without blocking binding

• Antibody framework selection: The choice between different antibody frameworks (e.g., ultralong CDRH3 of BLV1H12) can influence stability, solvent exposure, and functional properties .

• Fc region selection: Different Fc regions (IgG1, IgG4, etc.) influence effector functions like complement activation and Fc receptor engagement, which may be desirable or undesirable depending on experimental goals.

Understanding these structural considerations enables researchers to select or design antibodies with properties tailored to specific experimental requirements.

What is the role of CR4 in B cell migration and adhesion, and how can antibodies help elucidate these functions?

CR4 (CD11c/CD18) plays crucial roles in B cell migration and adhesion, particularly in activated memory B cells. Anti-CR4 antibodies can be used to investigate these functions through the following approaches:

• Adhesion pathway analysis:

  • CR4 contributes to the adhesion of activated B lymphocytes to various substrates

  • Anti-CR4 antibodies can block these interactions, revealing the relative contribution of CR4 versus other adhesion molecules

  • Comparative analysis using antibodies targeting different domains can reveal structure-function relationships

• Migration studies:

  • CR4 facilitates directed migration of activated B cells

  • Antibodies against CR4 can modulate this migration in transwell assays

  • Time-lapse microscopy combined with anti-CR4 antibodies can reveal the dynamics of CR4-mediated migration

• Signaling cascade investigation:

  • Anti-CR4 antibodies can be used to precipitate CR4 and associated molecules for signaling complex analysis

  • Phosphorylation studies after CR4 engagement or blockade reveal downstream pathways

Research indicates that CR4-mediated adhesion also promotes proliferation of BCR-activated cells, suggesting that CR4 is not merely a passive marker but a functional driver of memory B cell responses .

How can CR4 antibodies be engineered for enhanced specificity and functionality in research applications?

Advanced engineering of CR4 antibodies can enhance their research utility through several approaches:

• CDR grafting and modification:

  • Grafting of specific peptide sequences into CDRs, particularly CDRH3, can create antibodies with novel functions

  • Extensions of CDRs can allow antibodies to access recessed binding sites

  • β-hairpin conformations in CDRs can improve structural stability while maintaining binding specificity

• Alternative CDR engineering:

  • Beyond CDRH3, other CDRs such as CDRH2 can be modified for functional peptide grafting

  • CDRH2 is particularly solvent-exposed and makes minimal direct contact with the rest of the antibody structure

  • Engineering multiple CDRs in a single antibody can potentially create bifunctional research tools

• Expression optimization:

  • Codon optimization and removal of problematic sequence motifs can enhance expression yields

  • Selection of appropriate expression systems (mammalian, insect, bacterial) based on antibody complexity

  • Yield improvements have been observed when moving from CDRH3 to CDRH2 fusions (e.g., 5 mg/L to 17 mg/L)

These engineering approaches can create CR4 antibodies with tailored properties for specific research applications, enabling more precise studies of CR4 biology.

How can I resolve inconsistent staining patterns when using CR4 antibodies for flow cytometry?

Inconsistent staining patterns with CR4 antibodies in flow cytometry can arise from several factors. Here's a systematic approach to troubleshooting:

• Cell preparation variables:

  • Activation state: CR4 expression changes dramatically upon B cell activation; standardize activation protocols

  • Tissue source: CR4 expression varies between blood, tonsil, and other lymphoid tissues

  • Processing time: Delayed processing can alter surface marker expression

• Antibody-specific considerations:

  • Clone selection: Different anti-CR4 clones may recognize distinct epitopes

  • Titration: Perform detailed titration curves to determine optimal concentration

  • Fluorochrome selection: Some fluorochromes may cause steric hindrance or affect binding

• Protocol optimization:

  • Buffer composition: Test different staining buffers with varying protein concentrations

  • Incubation temperature: Compare room temperature versus 4°C staining

  • Fixation effects: If fixing cells, assess how fixation impacts epitope recognition

• Analysis approaches:

  • Implement standardized gating strategies using appropriate controls

  • Consider fluorescence minus one (FMO) controls for accurate boundary determination

  • Use methylated BSA to block Fc receptors and reduce non-specific binding

• Reference population inclusion:

  • Always include a positive control population (e.g., dendritic cells for CD11c)

  • Run parallel staining with alternative CR4 markers for confirmation

Creating a standardized operating procedure addressing these variables will significantly improve consistency across experiments.

What approaches can help distinguish true CR4 functional effects from experimental artifacts?

Distinguishing true CR4 functional effects from artifacts requires multiple complementary approaches:

• Multiple blocking methods:

  • Compare different anti-CR4 blocking antibody clones targeting distinct epitopes

  • Use small molecule inhibitors of CR4 where available

  • Implement genetic approaches (siRNA, CRISPR) to confirm antibody results

• Dose-response relationships:

  • Perform detailed dose-response curves with anti-CR4 antibodies

  • Establish correlation between blocking efficiency and functional outcomes

  • Use statistical methods to determine EC50 values

• Temporal analyses:

  • Implement time-course experiments to establish causality

  • Determine if observed effects follow expected temporal relationships

  • Use pulse-chase approaches to distinguish direct versus indirect effects

• Pathway validation:

  • Confirm that downstream signaling events match expected patterns

  • Verify that related pathways are affected as predicted

  • Use pathway inhibitors to confirm specificity

• Alternative model systems:

  • Compare results across different cell types/sources

  • If possible, validate key findings in primary cells versus cell lines

  • Consider in vivo validation where feasible

Implementing these approaches creates a matrix of evidence that can more confidently attribute observed effects to CR4 function.

How can I optimize CR4 antibody-based immunoprecipitation for protein interaction studies?

Optimizing CR4 antibody-based immunoprecipitation (IP) for protein interaction studies requires careful consideration of several technical aspects:

• Lysis buffer optimization:

  • Test different detergent types and concentrations to maintain CR4 complex integrity

  • Consider digitonin or CHAPS for milder extraction compared to Triton X-100

  • Include appropriate protease and phosphatase inhibitors

• Antibody selection and coupling:

  • Compare multiple anti-CR4 clones for IP efficiency

  • Evaluate direct antibody conjugation to beads versus protein A/G approaches

  • Consider orientation-specific coupling to maximize epitope accessibility

• IP protocol refinement:

  • Test different antibody:sample ratios to optimize signal-to-noise

  • Compare various incubation times and temperatures

  • Evaluate multiple washing stringencies to balance specificity versus sensitivity

• Validation approaches:

  • Perform reciprocal IPs when possible

  • Include isotype controls and CR4-negative samples

  • Confirm specificity through peptide competition or knockdown controls

• Advanced detection methods:

  • Consider crosslinking approaches to capture transient interactions

  • Implement proximity labeling techniques (BioID, APEX) as complementary approaches

  • Use quantitative proteomics with isobaric labeling to improve specificity determination

The combination of these optimization steps significantly increases the likelihood of identifying genuine CR4 interacting partners while minimizing background.

How are CR4 antibodies being utilized to understand the role of CR4 in B cell-mediated immune responses?

CR4 antibodies are enabling several new research directions in understanding B cell-mediated immunity:

• Memory B cell subset characterization:

  • Anti-CR4 antibodies are revealing previously unrecognized heterogeneity within memory B cell populations

  • CR4 expression correlates with class switching, suggesting involvement in B cell differentiation processes

  • Multiparameter flow cytometry with CR4 antibodies is helping establish new memory B cell classification systems

• Functional roles in immune responses:

  • Blocking CR4 with antibodies reveals its contributions to B cell adhesion, migration, and proliferation

  • These functions appear particularly important for memory B cell responses

  • CR4 blockade during recall responses may reveal its role in secondary immune responses

• Tissue localization studies:

  • Anti-CR4 antibodies in immunohistochemistry and imaging studies are mapping the anatomical distribution of CR4+ B cells

  • This helps understand how CR4 contributes to B cell localization within lymphoid tissues and at sites of inflammation

• Integration with T cell responses:

  • Research exploring how CR4+ B cells interact with different T cell populations

  • Anti-CR4 antibodies can help track these cells in co-culture systems

These approaches collectively establish CR4 not merely as a marker but as a functional component of memory B cell responses, potentially opening new therapeutic directions.

What methodological advances are improving the specificity and utility of CR4 antibodies?

Recent methodological advances are enhancing the specificity and research utility of CR4 antibodies:

• Rational antibody design approaches:

  • Structure-guided design based on CR4 protein structure

  • Computational optimization of CDR sequences for enhanced specificity

  • Antibody engineering platforms using machine learning to predict optimal binding properties

• Advanced screening technologies:

  • High-throughput screening of antibody libraries against native CR4 conformations

  • Single B cell sorting and antibody cloning from immunized sources

  • Phage display with structural constraints to mimic natural epitopes

• Novel conjugation strategies:

  • Site-specific conjugation technologies that preserve antibody binding properties

  • Smaller fluorophores with enhanced brightness and reduced steric hindrance

  • Multi-epitope targeting through bispecific antibody formats

• Validation methodologies:

  • CRISPR/Cas9-engineered cell lines for antibody specificity testing

  • Advanced imaging techniques to visualize antibody-target interactions

  • Comprehensive epitope mapping through hydrogen-deuterium exchange mass spectrometry

These methodological advances are creating a new generation of CR4 antibodies with enhanced specificity, functionality, and research applications.

How do CR4 antibodies help distinguish CR4 (CD11c/CD18) function from CR3 (CD11b/CD18) function?

Distinguishing CR4 (CD11c/CD18) from CR3 (CD11b/CD18) function is challenging due to their structural similarities as β2-integrins. CR4 antibodies help differentiate their functions through:

• Specificity verification:

  Property	CR4 (CD11c/CD18)	CR3 (CD11b/CD18)
  Expression pattern	Myeloid cells, activated memory B cells	Myeloid cells, NK cells
  Main ligands	iC3b, fibrinogen, ICAM-1	iC3b, fibrinogen, ICAM-1
  Primary functions	Adhesion, phagocytosis, migration	Adhesion, phagocytosis, migration
  Unique characteristics	Critical for activated B cell function	Dominant in neutrophil functions

• Selective blocking strategies:

  • Using CR4-specific antibodies alongside CR3-specific antibodies

  • Comparing effects of selective blocking to combined blocking

  • Analyzing residual function after selective blockade

• Genetic approaches:

  • Using cells from CD11c-deficient versus CD11b-deficient models

  • Selective knockdown of CD11c versus CD11b in cell culture

  • Reconstitution experiments with wild-type versus mutant forms

• Activation-specific studies:

  • Analyzing differential regulation of CR4 versus CR3 during cell activation

  • Tracking temporal expression patterns during B cell activation

These comparative approaches help delineate the unique contributions of CR4 to cellular functions, particularly in activated B cells where CR4 expression becomes prominent .

What experimental designs best reveal the unique contributions of CR4 to B cell function?

To reveal CR4's unique contributions to B cell function, the following experimental designs are most effective:

• Temporal expression analysis:

  • Track CR4 expression during B cell activation using flow cytometry

  • Correlate expression with functional changes and class switching

  • Identify critical time windows for CR4 function

• Selective blocking studies:

  • Compare B cell function with:

    • No blocking

    • CR4-specific blocking

    • Combined blocking of multiple adhesion molecules

  • Measure functional outcomes of adhesion, migration, and proliferation

  • Calculate the relative contribution of CR4 to each function

• Structure-function analysis:

  • Use domain-specific antibodies to block different regions of CR4

  • Engineer B cells expressing CR4 with specific domain mutations

  • Compare functional outcomes to map critical structural elements

• In vivo tracking and intervention:

  • Adoptive transfer of CR4+ versus CR4- B cells

  • In vivo antibody blocking studies

  • Analysis of memory responses with and without CR4 blockade

• Single-cell correlation studies:

  • Combine CR4 detection with functional readouts at single-cell level

  • Correlate CR4 expression levels with functional capabilities

  • Identify potential B cell subsets with differential CR4 dependency

These experimental designs collectively build a comprehensive understanding of CR4's specific contributions to B cell biology beyond other adhesion molecules.